Three scenarios can occur after spontaneous seroconversion from HBeAg to anti-HBe: Most individuals go into the inactive hepatitis B phase ("inactive carrier"), characterized by normalization of serum ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that it will be presenting new data from its Phase 2 trials evaluating the potential clinical impact that VIR-3434 ...
14d
AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
The AUSHINE study is a randomized, double-blind, multicenter Phase III trial evaluating the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with nucleos (t)ide ...
Hepatitis B viral load is the amount of hepatitis B virus (HBV) found in a person’s bloodstream. Hepatitis B is a viral infection that can pass from person to person through bodily fluids. It ...
SAN FRANCISCO, Sept. 18, 2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (collectively AusperBio), a clinical-stage biotechnology company advancing targeted ...
Arbutus Biopharma Corporation announced plans to initiate a Phase 2b clinical trial in the first half of 2025 after reporting promising results from its Phase 2a trial, where a significant functional ...
Dynavax's adult hepatitis B vaccine HEPLISAV-B is currently marketed in the US and is differentiated by its two-dose regimen over one month, which enables high levels of seroprotection faster than ...
Clinical Trials Arena on MSN
AusperBio concludes enrolment in Phase III AUSHINE trial
In September 2025, AusperBio completed participant enrolment in two Phase II studies evaluating AHB-137 for the functional cure of CHB. "AusperBio concludes enrolment in Phase III AUSHINE trial" was ...
First patient enrolled in ECLIPSE 1 Phase 3 clinical trial evaluating combination of tobevibart and elebsiran for chronic suppressive treatment ECLIPSE program designed to enable regulatory ...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it will be presenting new data from its ongoing Phase 2 SOLSTICE and MARCH trials evaluating the potential ...
Sanofi to acquire Dynavax, adding a marketed adult hepatitis B vaccine and phase 1/2 shingles candidate to the pipeline Paris, December 24, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback